Search Results
Aug 04, 2026, 14:52 ET America's 9-to-1 Health Spending Gap With Mexico Explains Lower Rehab Costs, TranquilHearts New Analysis Finds
$5,000 to $80,000 depending on the facility (National Center for Drug Abuse Statistics, 2024). At the premium end of the market, a month at a U.S. luxury rehab facility typically costs
More news about: TranquilHearts Private Luxury Rehab and Addiction Treatment Mexico
Aug 04, 2026, 12:00 ET Phylo and Chugai partner to advance AI agents in drug discovery
tools designed for the unique challenges of drug discovery research and capable of connecting insights across diverse sources of knowledge. We believe Biomni Lab can help our scientists explore scientific questions more effectively and accelerate our drug discovery to create innovative medicines for
More news about: Phylo, Inc.
Aug 04, 2026, 11:09 ET Disposable Syringes Market: USD 24.94 Billion by 2031 as Safety-Engineered Devices & Rising Injection Volumes Accelerate Market Expansion, Says Mordor Intelligence
adoption of injectable therapies. The market continues to expand as healthcare providers prioritize infection prevention, injection safety, and efficient drug-delivery solutions across hospitals, clinics, diagnostic centers, and home healthcare settings.
More news about: Mordor Intelligence Private Limited
Aug 04, 2026, 10:31 ET Lumbar Disc Herniation Market is Projected to Reach USD 7.2 Billion by 2036 as Novel Therapies and Minimally Invasive Treatments are Gaining Momentum | DelveInsight
addressing the underlying disc degeneration. Condoliase (SI-6603), developed by Seikagaku Corporation, is currently the only approved drug specifically indicated for LDH. Approved in Japan, it is administered as a single intradiscal injection that lowers intradiscal pressure by selectively
More news about: DelveInsight Business Research, LLP
Aug 04, 2026, 10:30 ET Research Use Recombinant Protein Market worth USD 1.55 billion by 2031 - Exclusive Report by MarketsandMarkets™
studies.Pharmaceutical & Biotechnology Companies accounted for the largest end-user share in 2025, fueled by increasing R&D investments and expanding drug discovery pipelines.Thermo Fisher Scientific Inc. (US), Bio-Techne (US), and Merck KGaA (Germany) emerged as the leading market players based
More news about: MarketsandMarkets
Aug 04, 2026, 10:03 ET A New PBM Contract Does Not Guarantee Better Results, SHARx Explains Why
the arrangement, who determines where members are allowed to fill specialty medication, and whether the vendor benefits when prescription volume or drug spending increases.That review should extend beyond the PBM named in the proposal. Employers should understand the roles of affiliated specialty
More news about: SHARx
Aug 04, 2026, 10:00 ET Q2BI Expands Asia-Pacific Footprint with New Offices in Taipei, Kuala Lumpur, and Melbourne
from first-in-human studies through FDA submissions.Since its founding, Q2BI has contributed to more than 1,800 clinical studies and over 50 New Drug Application (NDA) and Biologics License Application (BLA) approvals worldwide. Its teams have supported clinical programs across a broad range of therapeutic
More news about: Q-Square Business Intelligence (Q2BI)
Aug 04, 2026, 10:00 ET NIPRO Launches Expanded Hemodialysis with ELISIO™-HX to U.S. Providers Following FDA Clearance
U.S. commercial launch of ELISIO-HX, a medium-cutoff dialyzer featuring super high-flux membrane technology. Enabled by the recent U.S. Food and Drug Administration (FDA) 510(k) clearance of ELISIO-HX, NIPRO is introducing its expanded hemodialysis approach with a super high-flux membrane, or HDs
More news about: Nipro Medical Corporation
Aug 04, 2026, 08:30 ET Accelerate Translational Research with Quantitative Image Analysis, Upcoming Webinar Hosted by Xtalks
standardized methods and quality control improve the reproducibility of imaging results, strengthen human dose estimation and support greater confidence in drug development decisions.TORONTO, Aug. 4, 2026 /PRNewswire/ -- Preclinical
More news about: Xtalks
Aug 04, 2026, 08:30 ET AsymBio Secures US$184 Million Capital Injection to Support Long-Term Growth
investment aligns with Asymchem Group's differentiated, one-stop, end-to-end CDMO strategy.Globally, pipelines involving antibody-drug conjugates (ADCs), novel drug conjugates (NDCs), and bispecific and multispecific antibodies are advancing rapidly into clinical development. At the same time, outsourcing
More news about: AsymBio
Aug 04, 2026, 08:30 ET Prevent Pharmacy Copay Misuse Before It Erodes Millions in GTN, Upcoming Webinar Hosted by Xtalks
customers. Founded in 2020 and headquartered in Irvine, California, RIS Rx serves leading pharmaceutical manufacturers across a growing portfolio of drug brands.Learn more at
More news about: Xtalks
Aug 04, 2026, 08:21 ET FDA Grants Fast Track Designation to Xellsmart Off-The-Shelf Cell Therapy for Parkinson's Disease
Parkinson's disease—the world's second most prevalent neurodegenerative disorder — has been officially awarded Fast Track Designation (FTD) by the US Food and Drug Administration (FDA). This regulatory designation underscores the US health authority's recognition of XS411's clinical value and potential to address
More news about: XellSmart Biopharmaceutical Co., Ltd.
Aug 04, 2026, 08:15 ET Psilera Announces Fall Conference Schedule to Showcase Next-Generation Psychedelic and Neuroplastogen Pipeline
Fall Conference Schedule9th Annual Neuropsychiatric Drug Development Summit September 15 - 17, Boston, MAMagali Haas, MD-PhD, Chief Medical Officer, will participate
More news about: Psilera Inc.
Aug 04, 2026, 08:01 ET Pharmacy System Rewards the Wrong Results. It is Working as Designed
result."When Revenue Grows as Drug Spending RisesNational prescription drug spending increased 7.9% to $467 billion in 2024 after growing 10.8% the previous year, according to the Centers for Medicare & Medicaid Services (CMS). Retail prescription drug spending is also projected by the
More news about: SHARx
Aug 04, 2026, 08:00 ET Acosta Opens New Growth Channel for Manufacturers Through Salvatori-Scott Partnership
Aug. 4, 2026 /PRNewswire/ -- As health and wellness brands look beyond traditional retail for growth, the independent drug channel is emerging as an increasingly important opportunity. To help manufacturers capitalize on that shift,
More news about: Acosta
Aug 04, 2026, 08:00 ET Xtalks Announces its Life Science Webinar Calendar for August 2026
Upcoming free, educational webinars from Xtalks will feature topics on clinical trials, patient recruitment and retention, drug safety, laboratory technologies, pharmaceutical manufacturing and supply chain, commercialization and HEOR and preclinical research.TORONTO,
More news about: Xtalks
Aug 04, 2026, 08:00 ET Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation,
More news about: Nuvation Bio Inc.
Aug 04, 2026, 08:00 ET Triquetra Health Launches BioActive Vitamin B1™--First Complete Activation System with 5-11× More Usable B1 Plus the Cofactors That Unlock It
amazon.com/dp/B0G66V5VV9.Pharmacokinetic research published in the European Journal of Drug Metabolism and Pharmacokinetics demonstrates that benfotiamine achieves plasma thiamine bioavailability of 1,147% compared to standard thiamine
More news about: Triquetra Health LLC
Aug 04, 2026, 08:00 ET Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
are working diligently towards completing the next milestone. If we can develop a next-generation lithium product that would not require therapeutic drug monitoring, it would constitute a major improvement over current lithium-based treatments and positively impact the 43.5 million Americans afflicted
More news about: Alzamend Neuro, Inc.
Aug 04, 2026, 08:00 ET Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform. The drug consists of two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate, and a diffusion and cell penetration enhancer molecule ("SHAO")
More news about: Intensity Therapeutics Inc.
Aug 04, 2026, 08:00 ET Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
proprietary technology platform to develop innovative products with effective oral delivery. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable
More news about: Lipocine Inc.
Aug 04, 2026, 08:00 ET Revolune Announces Service Provider Program with CellCarta, Concept Life Sciences, and Propath UK
spatial and translational biology services, biomarker discovery and development capabilities, and exceptional end-to-end chemistry expertise to support drug discovery and development programs.About Propath UKPropath UK — The Spatial Biology CRO® — delivers the expertise, quality, and
More news about: Revolune
Aug 04, 2026, 08:00 ET Revolune Announces Service Provider Program with CellCarta, Concept Life Sciences, and Propath UK
spatial and translational biology services, biomarker discovery and development capabilities, and exceptional end-to-end chemistry expertise to support drug discovery and development programs.About Propath UKPropath UK — The Spatial Biology CRO® — delivers the expertise, quality, and
More news about: Revolune
Aug 04, 2026, 08:00 ET Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence
Aug. 4, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for BOTOX® Cosmetic (onabotulinumtoxinA)
More news about: AbbVie
Aug 04, 2026, 07:06 ET Galaxy Therapeutics Achieves CE Mark for SEAL™ Embolization System, Enabling Commercial Launch Across Europe and International Markets
markets while continuing to advance global regulatory initiatives, including review of its Premarket Approval (PMA) application by the U.S. Food and Drug Administration.About Galaxy TherapeuticsGalaxy Therapeutics is a privately held U.S.-based medical device company
More news about: Galaxy Therapeutics